


Long-Term Safety and Efficacy of Oral Deucricitbant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study

Marc A. Riedl¹, John Anderson², Emel Aygören-Pürsün³, Laurence Bouillet⁴, Hugo Chapelaine⁵, **Henriette Farkas**⁶, Delphine Gobert⁷, Roman Hakl⁸, Joshua S. Jacobs⁹, Ramón Lleonart¹⁰, Michael E. Manning¹¹, Avner Reshef¹², Giuseppe Spadaro¹³, Maria Staevska¹⁴, Marcin Stobiecki¹⁵, Giorgio Giannattasio¹⁶, Yumeng Li¹⁷, Peng Lu¹⁷, Justin Sun¹⁷, Ming Yu¹⁷, Anna Valerieva¹⁴

¹University of California San Diego, Division of Allergy and Immunology, La Jolla, CA, USA; ²AllerVieHealth, Clinical Research Center of Alabama, Birmingham, AL, USA; ³University Hospital Frankfurt, Goethe University Frankfurt, Department for Children and Adolescents, Frankfurt, Germany; ⁴Grenoble Alpes University, Laboratoire T-RAIG, UMR 5525 TIMC-IMAG (UGA-CNRS), National Reference Center for Angioedema (CREAK), Department of Internal Medicine, Grenoble, France; ⁵CHU de Montréal, Université de Montréal, Montréal, QC, Canada; ⁶Hungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary; ⁷Sorbonne Université, Médecine Interne, AP-HP, Centre de référence des angioedèmes à kinines, Hôpital Saint-Antoine, Paris, France; ⁸St. Anne's University Hospital in Brno and Faculty of Medicine, Masaryk University, Department of Clinical Immunology and Allergology, Brno, Czech Republic; ⁹Allergy and Asthma Clinical Research, Walnut Creek, CA, USA; ¹⁰Bellvitge University Hospital, L'Hospitalet de Llobregat, Allergology Service, Barcelona, Spain; ¹¹Allergy, Asthma and Immunology Associates, Ltd., Scottsdale, AZ, USA; ¹²Barzilai University Hospital, Allergy, Immunology and Angioedema Center, Ashkelon, Israel; ¹³University of Naples Federico II, Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), Napoli, Italy; ¹⁴Medical University of Sofia, Department of Allergology, Sofia, Bulgaria; ¹⁵Jagiellonian University Medical College, Department of Clinical and Environmental Allergology, Krakow, Poland; ¹⁶Pharvaris GmbH, Zug, Switzerland; ¹⁷Pharvaris Inc., Lexington, MA, USA

Key takeaways

Final Part A results from the RAPIDe-2 extension are consistent with the Phase 2 RAPIDe-1 study and provide further evidence on the long-term safety and efficacy of deucricitbant immediate-release (IR) capsule for treatment of repeat hereditary angioedema (HAE) attacks.



Background

- HAE:** a bradykinin-mediated condition with painful swelling attacks affecting multiple locations in the body.¹
- Current landscape:** guidelines recommend HAE attacks are treated as early as possible.²⁻⁴ Parenteral administration often leads to on-demand treatment of HAE attacks being delayed or forgone.⁵⁻⁸
- Oral deucricitbant:** a selective, bradykinin B2 receptor antagonist under development for both prophylactic and on-demand treatment of HAE attacks.⁹⁻¹⁶


Objective

Evaluate the long-term safety and efficacy of deucricitbant IR capsule for on-demand treatment of repeat HAE attacks in the RAPIDe-2 extension study.

Methods

- RAPIDe-2 (NCT05396105)*:** a two-part, double-blind, Phase 2/3 extension study.¹¹
- Part A eligible participants:** adults who completed RAPIDe-1 (NCT04618211).⁹
- Part A prophylaxis:** no long-term HAE prophylaxis treatment was allowed. Recent use of long-term HAE prophylaxis treatment prior to screening was allowed provided a pre-specified washout period was observed.

Figure 1. RAPIDe-2 study design



Methods

- Primary endpoint:** safety including treatment-emergent adverse events (TEAEs), clinical laboratory tests, vital signs, and electrocardiogram findings.
- Secondary endpoints:** efficacy endpoints using patient-reported outcome tools.
- Data collection:** pre-specified at pre-treatment, hourly for 6 hours, and at 8, 12, 24, and 48 hours post-treatment.

Figure 2. Efficacy assessment scales




Table 1. Efficacy endpoints

Key efficacy endpoints	Defined as
Time to and proportion of attacks achieving:	
Onset of symptom relief	PGI-C rating of at least "a little better" for 2 consecutive timepoints by 12 hours ^a
Substantial symptom relief	PGI-C rating of at least "better" for 2 consecutive timepoints by 12 hours ^a
Reduction in attack severity	≥1-level reduction in the PGI-S from pre-treatment for 2 consecutive timepoints by 12 hours ^a
Complete attack resolution	PGI-S rating of "none" at 24 hours ^b

PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity. ^aIf rescue medication used within 14.5 hours post-treatment, time to event was censored at 14.5 hours regardless of whether event occurred within 12 hours post-treatment. ^bRescue medication use within 33.5 hours post-treatment was regarded as not achieving complete attack resolution at 24 hours.

Post-hoc analyses

- Durability of treatment response:** the achievement and maintenance of serial milestones of symptom relief and resolution without recurrence of symptoms following a single dose of deucricitbant only.
 - Symptom recurrence:** following the achievement of each efficacy milestone, symptom recurrence was evaluated as any instance where the milestone was no longer being met within 24 hours.
- Upper airway attacks:** confirmed by investigators and defined as swelling of the lips/tongue or any sensation of lump in the throat, difficulty swallowing, or voice change (assessed with AMRA-5).

Results

Data:

- RAPIDe-2 Part A included 465 attacks from 19 participants. Combined dose-blinded group data shown.

Table 2. Participant characteristics

Participant characteristics	Deucricitbant IR capsule (combined dose group) ^a (N=19)
Age in years, mean (SD)	44.4 (17.6)
Sex: male/female, n (%)	7 (36.8) / 12 (63.2)
Race: White/other, n	18 / 1
BMI, mean (SD)	26.8 (4.0)
Years since HAE diagnosis, mean (SD)	23.3 (15.2)
HAE type, n (%)	
HAE-1	17 (89.5)
HAE-2	2 (10.5)

BMI, body mass index; HAE, hereditary angioedema; IR, immediate-release; SD, standard deviation. ^aAll participants who received any dose of deucricitbant in the study. Study baseline refers to results at the screening or enrollment visit of RAPIDe-2 Part A. For parameters whose values remain constant over time, baseline values from RAPIDe-1 were used. For parameters without results at the screening or enrollment visit of RAPIDe-2 or for parameters not collected at that time, the last available assessment in RAPIDe-1 was used as the baseline values. Data for combined dose group shown (deucricitbant 10 mg, 20 mg, and 30 mg).

Results

Safety analysis

- Participants who received ≥1 dose of deucricitbant IR capsule in the study.
- No treatment-related TEAEs.
- No treatment-related serious or severe TEAEs, no treatment-related TEAEs in laboratory parameters, vital signs, or ECG findings.
- No TEAEs leading to treatment discontinuation, study withdrawal, or death.

Table 3. TEAEs within 3 days of study drug administration

Adverse events	Deucricitbant IR capsule (combined dose group) (N=19; A=465)
Attacks with any TEAE, n (%)	12 (2.6)
Treatment-related TEAEs, n	0
Serious TEAEs, n	1 ^a
Treatment-related serious TEAEs, n	0
TEAEs leading to study drug discontinuation, study withdrawal, or death, n	0

ECG, electrocardiogram; IR, immediate-release; TEAE, treatment-emergent adverse event, defined as adverse event occurring from first study drug administration. A = number of treated attacks. N = number of participants. ^aTooth caries unrelated to treatment. Data for combined dose group shown (deucricitbant 10 mg, 20 mg, and 30 mg).

Efficacy analysis


- Modified intention-to-treat analysis set: participants who treated ≥1 attack with deucricitbant IR capsule and non-missing PGI-C results from ≥1 post-treatment timepoint.

Figure 3. Median time to achieving key efficacy endpoints



CI, confidence interval; PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity. ^aPGI-C rating of at least "a little better" for 2 consecutive timepoints by 12 hours post-treatment regardless of any missing intervening assessments and without rescue medication use. ^bWithin-participant correlation was not accounted for in all Kaplan-Meier estimates. ^cPGI-C rating of at least "better" for 2 consecutive timepoints by 12 hours post-treatment regardless of any missing intervening assessments and without rescue medication use. ^d≥1 point reduction in PGI-S from pre-treatment for 2 consecutive timepoints by 12 hours post-treatment and without rescue medication use. ^ePGI-S rating of "none" within 48 hours post-treatment and without rescue medication use.


Figure 4. Majority of attacks achieved key efficacy endpoints



PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity. A = number of study-drug treated attacks that achieved the efficacy milestone with a single dose of deucricitbant. ^aDefined as PGI-C rating remaining "same" or better within 24 hours after reaching "a little better" for 2 consecutive timepoints within 12 hours post-treatment. ^bDefined as PGI-S rating better than "none" within 24 hours after reaching "none" within 24 hours post-treatment. Combined dose group data shown (deucricitbant 10 mg, 20 mg, and 30 mg).

Results


Figure 5. Majority of attacks treated with a single dose of deucricitbant and without rescue medication



IR, immediate-release. A = number of attacks. Data for combined dose group shown (deucricitbant 10 mg, 20 mg, and 30 mg). ^aProportion of attacks that were not treated with rescue medication within 24 hours post-treatment; 8 attacks used rescue medication within 24 hours post-treatment. ^bProportion of attacks achieving complete attack resolution, defined as achieving PGI-S rating of "none" at the last available timepoint before or at 24 hours post-treatment without use of rescue medication.

Durability of response to treatment

Figure 6. Over 98% of attacks that achieved symptom relief or resolution with a single dose of deucricitbant had a durable response without symptom recurrence



PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity. A = number of study-drug treated attacks that achieved the efficacy milestone with a single dose of deucricitbant. ^aDefined as PGI-C rating remaining "same" or better within 24 hours after reaching "a little better" for 2 consecutive timepoints within 12 hours post-treatment. ^bDefined as PGI-S rating better than "none" within 24 hours after reaching "none" within 24 hours post-treatment. Combined dose group data shown (deucricitbant 10 mg, 20 mg, and 30 mg).

Treatment outcomes of upper airway attacks

- Of 465 attacks, 14 were upper airway, including laryngeal, attacks without breathing difficulties.
- Similar times to symptom relief and resolution were observed for upper airway attacks and other attacks.

This presentation includes data for an investigational product not yet approved by regulatory authorities.

References

- Busse PJ, et al. *N Engl J Med.* 2020;382:1136-48. 2. Betschel S, et al. *Allergy Asthma Clin Immunol.* 2019;15:72. 3. Busse PJ, et al. *J Allergy Clin Immunol Pract.* 2021;9:132-50. 4. Maurer M, et al. *Allergy.* 2022;77:1961-90. 5. Center for Biologics Evaluation and Research. The voice of the patient—hereditary angioedema. US Food and Drug Administration; May 2018. <https://www.fda.gov/media/113509/download>. Accessed May 20, 2025. 6. Betschel SD, et al. *Allergy Asthma Clin Immunol.* 2024;20:43. 7. Covella B, et al. *Future Pharmac.* 2024;4:41-53. 8. Radjoicic C, et al. *Allergy Asthma Proc.* 2021;42. 9. RAPIDe-1 <https://www.clinicaltrials.gov/study/NCT04618211>. Accessed May 20, 2025. 10. Maurer M, et al. Presented at: AAAAI; February 24–27, 2023; San Antonio, TX, USA. 11. RAPIDe-2. <https://clinicaltrials.gov/study/NCT05396105>. Accessed May 20, 2025. 12. RAPIDe-3. <https://www.clinicaltrials.gov/study/NCT06343779>. Accessed May 20, 2025. 13. CHAPTER 1. <https://www.clinicaltrials.gov/study/NCT05047185>. Accessed May 20, 2025. 14. CHAPTER 3. <https://clinicaltrials.gov/study/NCT0669754>. Accessed May 20, 2025. 15. CHAPTER 4. <https://clinicaltrials.gov/study/NCT06679881>. Accessed May 20, 2025. 16. Aygören-Pürsün E, et al. Presented at: EAACI; May 31–June 3, 2024; Valencia, Spain. 17. Cohn DM, et al. *Clin Transl Allergy.* 2023;e12288.